ReviewCurrent opinion in oncology2010
Recent updates in renal cell carcinoma.
Review in Current opinion in oncology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 40 citations in OpenAlex.
- A Comprehensive Study on Signal Transduction and Therapeutic Role of miR-877 in Human Cancers.Advanced biomedical research · 2023Review
- A Rare Presentation of Metastatic Renal Cell Carcinoma Masquerading as Vitritis: A Case Report and Review of Literature.Diagnostics (Basel, Switzerland) · 2022Article
- The Prominent Role of miR-942 in Carcinogenesis of Tumors.Advanced biomedical research · 2022Review
- Knockdown of CHCHD2 inhibits migration and angiogenesis of human renal cell carcinoma: A potential molecular marker for treatment of RCC.Oncology letters · 2019Article
- Tumor Associated Macrophages in Kidney Cancer.Analytical cellular pathology (Amsterdam) · 2016Review
- Article
- Molecular and immunologic markers of kidney cancer-potential applications in predictive, preventive and personalized medicine.The EPMA journal · 2015Review
- The emerging role of extracellular vesicles as biomarkers for urogenital cancers.Nature reviews. Urology · 2014Review
- Eg5 inhibitor, a novel potent targeted therapy, induces cell apoptosis in renal cell carcinoma.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2014Article
- Interferon-α enhances the susceptibility of renal cell carcinoma to rapamycin by suppressing mTOR activity.Experimental and therapeutic medicine · 2014Article
- Article
- Oncogenic micro-RNAs and Renal Cell Carcinoma.Frontiers in oncology · 2014Review
- Gene expression profiling of the synergy of 5-aza-2'-deoxycytidine and paclitaxel against renal cell carcinoma.World journal of surgical oncology · 2012Article
- Article
- Solid renal masses in adults.The Indian journal of radiology & imagingArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
purpose of reviewThe review will examine the recent advances in our understanding of the genetic and molecular events that shape this cancer, and overview the emerging targeted therapies that have altered the landscape for renal cell carcinoma (RCC) patients. RECENT
findingsThe incidence of RCC continues to rise, making it the 7th and 8th most common cancer among men and women in the US, respectively. Von Hippel-Lindau (VHL) gene loss is an important factor in the development of clear cell RCC, however: loss of VHL can result in tumors which express both HIF1 and HIF2, or HIF2 alone, correlating with distinct pathway activities. Invasive tumors demonstrating loss of VHL consistently demonstrate additional genetic changes, which appear to be essential for tumor progression. Targeted therapies have demonstrated improvements in overall survival. New ways to radiographically measure the tumor response to these treatments may provide additional information about a drug's activity in an individual patient. Vascular endothelial growth factor receptor tyrosine kinase inhibitors are still being investigated in the adjuvant setting. SUMMARY: The field of RCC biology continues to rapidly change. As new targeted strategies to control this cancer evolve, so do both the clinical strategies, and the strategies to measure response and predict outcome.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.